Gensco Pharma® Acquires Global Rights and IP for RizaFilm® and RizaPort®
Gensco Pharma acquires global rights to RizaFilm® and RizaPort®, with a U.S. migraine treatment launch planned for Q4 2025 and global expansion ahead.
Gensco® Pharma Announces RizaFilm® Commercialization Update in the United States
Gensco® Pharma, a specialty pharmaceutical company, in partnership with IntelGenx is announcing the anticipated launch of RizaFilm® for Q1-2024. RizaFilm® is based on IntelGenx’s proprietary VersaFilm® technology and is patent protected until 2034. As the NDA holder, Gensco® will begin commercialization of the 10mg Film and will continue to fund the expanded indications for the 5mg Pediatric dose.
RizaFilm® is a film formulation of rizatriptan and the only oral dissolvable film available for the treatment of acute migraines. RizaFilm® has ease of convenience and does not require a drink for swallowing, thus allowing for rapid administration and relief from migraine related pain and nausea.
Skin Tears Treatment Market to Observe Strong Development by 2018-2026
[To download a printable version of this article, click here] MARKET RESEARCH April 12, 2019 / kalyani badkas Skin tears have become a common issue among people of older age as the skin becomes more delicate and drier and so skin tears treatment has become an...Gensco® Pharma Partners with IntelGenx to Launch and Commercialize RIZAFILM® (U.S. market name for RIZAPORT® — Rizatriptin Oral Film) in the United States
Miami, Florida, December 12, 2018 – Gensco® Pharma, a leading specialty pharmaceutical manufacturer specializing in development and commercialization of prescription transdermal products, today announced the execution of a definitive licensing, development and supply...AAP Issues Flu Vaccine Recommendations for 2018-2019
All children should receive the flu shot as soon as it is available: AAP [To download a printable version of this article, click here] ITASCA, IL. – The American Academy of Pediatrics (AAP) recommends that all children ages 6 months and older receive a flu shot this...
The Only FDA-Approved Prescription Hydrogel and 4% Lidocaine HCl for Debridement and Wound Pain Management
Astero® provides fast relief for painful wounds as fast as 3-5 minutes. Available by prescription only, Astero® is indicated for the relief of painful wounds and wound healing such as ulcerations, pressure wounds, first and second degree burns, post-surgical...
An Exploratory, Single-blind Study to Evaluate Both the Onset of Anesthesia of LiDORx® in Patients Aged 18–88 Years
By Patrick Hardigan, BS, MS, PhD, Nova Southeastern University, Director of Clinical Research Background Fear of pain is one reason a patient may be apprehensive about a medical procedure. The most common form of pain control, namely local anesthesia, can itself...
Now Available Through Federal Supply Schedule (FSS)
Contract #V797D-70219 The Only FDA-Approved Prescription Hydrogel and 4% Lidocaine HCl for Pain Associated with Wound Healing and Vasculitis FDA Approved #K092086 Astero®, manufactured by Gensco Pharma, is now available through the Federal Supply Schedule. Astero®...
Physician Explores Gout Treatment Options
As seen in Chain Drug Review | May 15, 2017 MIAMI — Gout is an extremely painful form of inflammatory arthritis and the most common form of this type of arthritis in men, according to Dr. Gary Myerson, a founding fellow of the American College of Rheumatology....
Reduce Patients’ Gout Pain…
…“At the Site” and In Their Pocket Chain Drug Review | April 24, 2017 Gensco Pharma Introduces the First Complete Gout Savings Program The innovative ColciGel® Allopurinol Voucher Program offers patients affordable access to ColciGel® for acute gout flares and...LOOKING TO THE FUTURE
Launching in Q4 2025, RizaFilm® delivers fast, water-free migraine relief through novel oral dissolvable film (ODF) technology.